Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to ...

The Opal platform offers eye care professionals a complementary tool for patients, featuring order tracking, appointment ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Opal, a digital e-commerce ...

Larry Biegelsen, an analyst from Wells Fargo, assigned the Buy rating on Bausch + Lomb Corporation (BLCO – Research Report). The associated price target remains the same with $23.00. Larry ...

Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...

Investing.com -- Bausch + Lomb (NYSE:BLCO) is exploring a potential sale as part of an effort to resolve issues related to its separation from parent company Bausch Health, which is burdened with ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Blackstone, Advent International and TPG are among a long list of private equity firms studying bids for ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

Eyecare company is working with Goldman Sachs on a deal that would extricate it from its indebted parent, the Financial Times reported The stock of eyecare company Bausch + Lomb Corp. was up 14%on ...

As part of the deal, Bausch + Lomb will help scale commercialization of Trukera’s ScoutPro Osmolarity System, a device that measures tear osmolarity, or the salt content of a person’s tears, to help ...